ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab ...
Post-hoc analyses of the phase III ARCADIA and OLYMPIA clinical trial programs, published in the Journal of the European Academy of Dermatology and Venereology, highlight nemolizumab’s fast onset of ...
The LIBERTY-PN PRIME and PRIME2 trials investigated itch response to dupilumab among patients who have prurigo nodularis. There were 151 participants in PRIME (dupilumab, n = 75) from 58 study sites ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results